Skip to main content
. 2019 Sep 4;12:183–204. doi: 10.2147/IJNRD.S215370

Figure 3.

Figure 3

Sustained increase in platelet count during ongoing eculizumab treatment in trial 1 data (from Soliris (Eculizumab) highlights of prescribing information. US Food and Drug Administration. 2007. Available from: https://www.access data.fda.gov/drugsatfda_docs/label/2011/125166s172lbl.pdf36) (bars represent SD); normalization of platelet count was defined as count >150±109/L).